CLINICAL TRIALS PROFILE FOR BEPREVE

All Clinical Trials for bepreve

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00424398 ↗	Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis	Completed	Bausch & Lomb Incorporated	Phase 2/Phase 3	2007-02-01	The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
NCT00586625 ↗	Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers	Completed	Bausch & Lomb Incorporated	Phase 3	2007-10-01	Safety study for bepotastine besilate ophthalmic solution in normal volunteers
NCT01128556 ↗	The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing	Completed	North Texas Institute for Clinical Trials	Phase 4	2010-04-01	To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.
NCT01337557 ↗	Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses	Unknown status	Bausch & Lomb Incorporated	Phase 4	2011-05-01	The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.
NCT01337557 ↗	Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses	Unknown status	Hom, Milton M., OD, FAAO	Phase 4	2011-05-01	The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.
NCT01346371 ↗	The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer	Completed	Bausch & Lomb Incorporated	Phase 4	2011-05-01	The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
NCT01346371 ↗	The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer	Completed	Minnesota Eye Consultants, P.A.	Phase 4	2011-05-01	The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.

Clinical Trial Conditions for bepreve

Condition Name

Condition Name for bepreve
Intervention	Trials
Allergic Conjunctivitis	4
Conjunctivitis, Allergic	1
Eye Allergies	1
Histamine Responsive Allergy Patients	1

Condition MeSH

Condition MeSH for bepreve
Intervention	Trials
Conjunctivitis, Allergic	5
Conjunctivitis	5
Hypersensitivity	1

Clinical Trial Locations for bepreve

Trials by Country

Trials by Country for bepreve
Location	Trials
United States	5

Trials by US State

Trials by US State for bepreve
Location	Trials
California	2
Tennessee	1
Minnesota	1
Texas	1

Clinical Trial Progress for bepreve

Clinical Trial Phase

Clinical Trial Phase for bepreve
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for bepreve
Clinical Trial Phase	Trials
Completed	6
Unknown status	1

Clinical Trial Sponsors for bepreve

Sponsor Name

Sponsor Name for bepreve
Sponsor	Trials
Bausch & Lomb Incorporated	4
Minnesota Eye Consultants, P.A.	1
Southern California College of Optometry	1

Sponsor Type

Sponsor Type for bepreve
Sponsor	Trials
Other	5
Industry	5